Vaxart (VXRT) Competitors $0.35 -0.01 (-2.23%) As of 10/7/2025 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VXRT vs. CTNM, UPXI, ENGN, ENTA, EDIT, ALDX, MREO, ALEC, ACIU, and TKNOShould you be buying Vaxart stock or one of its competitors? The main competitors of Vaxart include Contineum Therapeutics (CTNM), Upexi (UPXI), enGene (ENGN), Enanta Pharmaceuticals (ENTA), Editas Medicine (EDIT), Aldeyra Therapeutics (ALDX), Mereo BioPharma Group (MREO), Alector (ALEC), AC Immune (ACIU), and Alpha Teknova (TKNO). These companies are all part of the "pharmaceutical products" industry. Vaxart vs. Its Competitors Contineum Therapeutics Upexi enGene Enanta Pharmaceuticals Editas Medicine Aldeyra Therapeutics Mereo BioPharma Group Alector AC Immune Alpha Teknova Vaxart (NASDAQ:VXRT) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk. Do analysts rate VXRT or CTNM? Vaxart presently has a consensus target price of $2.00, indicating a potential upside of 469.80%. Contineum Therapeutics has a consensus target price of $22.20, indicating a potential upside of 94.91%. Given Vaxart's higher possible upside, equities analysts clearly believe Vaxart is more favorable than Contineum Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaxart 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Contineum Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.00 Does the media favor VXRT or CTNM? In the previous week, Contineum Therapeutics had 1 more articles in the media than Vaxart. MarketBeat recorded 1 mentions for Contineum Therapeutics and 0 mentions for Vaxart. Vaxart's average media sentiment score of 0.55 beat Contineum Therapeutics' score of -0.20 indicating that Vaxart is being referred to more favorably in the media. Company Overall Sentiment Vaxart Positive Contineum Therapeutics Neutral Do institutionals and insiders believe in VXRT or CTNM? 18.0% of Vaxart shares are owned by institutional investors. 2.8% of Vaxart shares are owned by insiders. Comparatively, 11.3% of Contineum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more volatility & risk, VXRT or CTNM? Vaxart has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500. Comparatively, Contineum Therapeutics has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500. Which has better earnings and valuation, VXRT or CTNM? Contineum Therapeutics has higher revenue and earnings than Vaxart. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Vaxart, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaxart$47.40M1.70-$66.95M-$0.25-1.40Contineum Therapeutics$50M6.39-$42.26M-$2.20-5.18 Is VXRT or CTNM more profitable? Contineum Therapeutics has a net margin of 0.00% compared to Vaxart's net margin of -122.63%. Contineum Therapeutics' return on equity of -29.75% beat Vaxart's return on equity.Company Net Margins Return on Equity Return on Assets Vaxart-122.63% -91.89% -38.40% Contineum Therapeutics N/A -29.75%-28.08% SummaryContineum Therapeutics beats Vaxart on 10 of the 16 factors compared between the two stocks. Get Vaxart News Delivered to You Automatically Sign up to receive the latest news and ratings for VXRT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VXRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VXRT vs. The Competition Export to ExcelMetricVaxartMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$80.36M$2.66B$6.12B$10.65BDividend YieldN/A56.92%5.69%4.74%P/E Ratio-1.3023.8685.6126.85Price / Sales1.70745.61612.81135.13Price / CashN/A169.9037.7861.77Price / Book1.355.5913.256.70Net Income-$66.95M$32.78M$3.30B$276.44M7 Day Performance-7.14%4.01%3.87%2.48%1 Month Performance-8.83%10.63%8.33%8.79%1 Year Performance-55.16%-1.80%88.97%34.41% Vaxart Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VXRTVaxart2.4091 of 5 stars$0.35-2.2%$2.00+469.8%-56.6%$80.36M$47.40M-1.30120CTNMContineum Therapeutics2.4703 of 5 stars$11.82-0.8%$22.20+87.8%-34.1%$331.43M$50M-5.3731Positive NewsUPXIUpexi2.4871 of 5 stars$5.62+7.7%$15.50+175.8%+171.2%$330.96M$15.81M0.00130Short Interest ↑ENGNenGene3.1945 of 5 stars$6.45-0.6%$19.50+202.3%+4.8%$330.18MN/A-3.3931ENTAEnanta Pharmaceuticals3.9641 of 5 stars$15.16+91.9%$20.20+33.2%-4.1%$324.12M$67.64M-3.51160High Trading VolumeEDITEditas Medicine4.2373 of 5 stars$3.52+8.6%$5.10+44.9%+22.4%$316.52M$32.31M-1.24230News CoverageGap UpALDXAldeyra Therapeutics2.2649 of 5 stars$5.21+2.8%$9.50+82.3%+6.3%$312.08MN/A-6.1310MREOMereo BioPharma Group2.404 of 5 stars$1.96+1.0%$7.40+277.6%-54.1%$311.64M$10M-28.0040Positive NewsALECAlector3.7346 of 5 stars$3.05-1.6%$4.17+36.6%-32.1%$308.69M$100.56M-2.63270News CoverageACIUAC Immune2.1404 of 5 stars$3.04+7.0%$10.00+228.9%+5.6%$305.25M$31.02M-5.24140Positive NewsTKNOAlpha Teknova1.6161 of 5 stars$5.65-6.9%$10.00+77.0%+8.3%$302.36M$38.92M-13.45240 Related Companies and Tools Related Companies Contineum Therapeutics Competitors Upexi Competitors enGene Competitors Enanta Pharmaceuticals Competitors Editas Medicine Competitors Aldeyra Therapeutics Competitors Mereo BioPharma Group Competitors Alector Competitors AC Immune Competitors Alpha Teknova Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VXRT) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredGet my No. 1 gold stock nowGold recently broke past $3,800 per ounce – setting yet another new all-time high. And Wall Street banks sa...Stansberry Research | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredU.S. Government Blocked NVIDIA’s Buyout… Here’s WhyThe U.S. government doesn't normally block billion-dollar tech deals. But when NVIDIA tried to acquire this...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored"I'm risking my reputation on this"My prediction: Q4 2025 won't just be another seasonal crypto pump. It will be the quarter that sparks a crypto...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxart, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxart With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
